The rise and fall of pneumococcal serotypes carried in the PCV era

Vaccine

Volumn 35, Issue 9, 2017, Pages 1293-1298

  Devine, Vanessa T ^a   Cleary, David W ^a   Jefferies, Johanna M C ^a,b   Anderson, Rebecca ^a   Morris, Denise E ^a   Tuck, Andrew C ^a   Gladstone, Rebecca A ^a,c   O'Doherty, Grace ^a   Kuruparan, Priyasharmila ^a   Bentley, Stephen D ^c   Faust, Saul N ^a,b   Clarke, Stuart C ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Pneumococcal conjugate vaccines; Serotype replacement; Streptococcus pneumoniae; Whole genome sequencing

Indexed keywords

PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; VACCINE;

ARTICLE; BACTERIUM ISOLATE; CHILD; DISEASE SURVEILLANCE; HUMAN; MAJOR CLINICAL STUDY; PNEUMOCOCCAL INFECTION; PREVALENCE; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; WHOLE GENOME SEQUENCING; WINTER; BACTERIAL GENOME; CLASSIFICATION; DNA SEQUENCE; FEMALE; GENETICS; HETEROZYGOTE; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; NASOPHARYNX; PRESCHOOL CHILD; UNITED KINGDOM;

CARRIER STATE; CHILD, PRESCHOOL; FEMALE; GENOME, BACTERIAL; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; INFANT; MALE; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREVALENCE; SEQUENCE ANALYSIS, DNA; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; UNITED KINGDOM; VACCINES, CONJUGATE;

EID: 85011105574     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.01.035     Document Type: Article

References (29)

1. [1] European Centre for Disease Prevention and Control. Annual epidemiological report 2014 – vaccine preventable diseases – invasive bacterial disease < http://ecdc.europa.eu/>.
2. [2] Centers for Disease Control and Prevention. 2014. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae; 2014.
3. [3] Sleeman, K.L., Daniels, L., Gardiner, M., et al. Acquisition of Streptococcus pneumoniae and nonspecific morbidity in infants and their families: a cohort study. Pediatr Infect Dis J 24:2 (2005), 121–127.
4. [4] Mastro, T.D., Nomani, N.K., Ishaq, Z., et al. Use of nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in Pakistan for surveillance for antimicrobial resistance. Pediatr Infect Dis J 12:10 (1993), 824–830.
5. [5] Aniansson, G., Alm, B., Andersson, B., et al. Nasopharyngeal colonization during the first year of life. J Infect Dis 165:Suppl 1 (1992), S38–S42.
6. [6] Principi, N., Marchisio, P., Schito, G.C., Mannelli, S., Ascanius Project Collaborative Group. Risk factors for carriage of respiratory pathogens in the nasopharynx of healthy children. Pediatr Infect Dis J 18:6 (1999), 517–523.
7. [7] Brueggemann, A.B., Griffiths, D.T., Meats, E., Peto, T., Crook, D.W., Spratt, B.G., Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 187:9 (2003), 1424–1432.
8. [8] Donaldson L, Beasley C, Howe J. Planned changes to the routine Childhood Immunisation Programme. Department of Health National Archives 2006; < http://webarchive.nationalarchives.gov.uk/20130107105354/>, < http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_4128120>.
9. [9] Rodrigo, C., Lim, W.S., The relevance of pneumococcal serotypes. Curr Infect Dis Rep, 16(4), 2014, 403.
10. [10] Liesenborghs, L., Verhaegen, J., Peetermans, W.E., Vandeven, J., Flamaing, J., Trends in serotype prevalence in invasive pneumococcal disease before and after infant pneumococcal vaccination in Belgium, 2002–2010. Vaccine 31:11 (2013), 1529–1534.
11. [11] Ardanuy, C., Tubau, F., Pallares, R., Calatayud, L., Domínguez, M.A., Rolo, D., et al. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997–2007. Clin Infect Dis 48:1 (2009), 57–64.
12. [12] Miller, E., Andrews, N.J., Waight, P.A., Slack, M.P., George, R.C., Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 11:10 (2011), 760–768.
13. [13] Moore, C.E., Paul, J., Foster, D., Mahar, S.A., Griffiths, D., Knox, K., et al. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis 210:7 (2014), 1001–1011.
14. [14] Moore, M.R., Link-Gelles, R., Schaffner, W., Lynfield, R., Lexau, C., Bennett, N.M., et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 15:3 (2015), 301–309.
15. [15] Kyaw, M.H., Lynfield, R., Schaffner, W., Craig, A.S., Hadler, J., Reingold, A., et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354 (2006), 1455–1463.
16. [16] Kim, L., McGee, L., Tomczyk, S., Beall, B., Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective. Clin Microbiol Rev 29 (2016), 525–552.
17. [17] Waight, P.A., Andrews, N.J., Ladhani, S.N., Sheppard, C.L., Slack, M.P.E., Miller, E., Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 15:5 (2015), 535–543.
18. [18] Tocheva, A.S., Jefferies, J.M., Christodoulides, M., Faust, S.N., Clarke, S.C., Distribution of carried pneumococcal clones in UK children following the introduction of the 7-valent pneumococcal conjugate vaccine: a 3–year cross-sectional population based analysis. Vaccine 31:31 (2013), 3187–3190.
19. [19] Gladstone, R.A., Jefferies, J.M., Tocheva, A.S., Beard, K.R., Garley, D., Chong, W.W., et al. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction. Vaccine 33:17 (2015), 2015–2021.
20. [20] Zerbino, D.R., Birney, E., Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res 18:5 (2008), 821–829.
21. [21] Victorian Bioinformatics Consortium, Velvet optimiser. , 2008 [accessed 2015].
22. [22] Tocheva, A.S., Jefferies, J.M., Rubery, H., Bennett, J., Afimeke, G., Garland, J., et al. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Vaccine 29:26 (2011), 4400–4404.
23. [23] Croucher, N.J., Finkelstein, J.A., Pelton, S.I., Mitchell, P.K., Lee, G.M., Parkhill, J., et al. Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet 45 (2013), 656–663.
24. [24] Public Health England. Pneumococcal disease: cases caused by strains covered by Prevenar 13 vaccine. < http://www.gov.uk/government/publications/pneumococcal-disease-cases-caused-by-strains-covered-by-prevenar-13-vaccine/pneumococcal-disease-cases-caused-by-strains-covered-by-prevenar-13-vaccine>.
25. [25] Lindstrand, A., Galanis, I., Darenberg, J., Morfeldt, E., Naucler, Blennow M., et al. Unaltered pneumococcal carriage prevalence due to expansion of non-vaccine types of low invasive potential 8 years after vaccine introduction in Stockholm. Sweden Vaccine 34:38 (2016), 4565–4571, 10.1016/j.vaccine.2016.07.031.
26. [26] Desai, A.P., Sharma, D., Crispell, E.K., Baughman, W., Thomas, S., Tunali, A., et al. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J 34:11 (2015), 1168–1174, 10.1097/INF.0000000000000849.22.
27. [27] van der Linden, M., Falkenhorst, G., Perniciaro, S., Imöhl, M., Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS ONE, 10(7), 2015, e0131494, 10.1371/journal.pone.0131494.
28. [28] van der Linden, M., Perniciaro, S., Imöhl, M., Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis, 15, 2015, 207, 10.1186/s12879-015-0941-9.
29. [29] Steens, A., Caugant, D.A., Aaberge, I.S., Vestrheim, D.F., Decreased carriage and genetic shifts in the Streptococcus pneumoniae population after changing the 7-valent to the 13-valent pneumococcal vaccine in Norway. Pediatr Infect Dis J 34:8 (2015), 875–883, 10.1097/INF.0000000000000751.